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Abstract
Background: Activation of herpes virus 6 (HHV6) has seen in Hodgkin’s and non-Hodgkin’s Lymphoma (HL&NHL)
as a result of lymphoma associated immunosuppression. Multiple studies have suggested an association between
both HHV6 and cytomegalovirus CMV for development of CMV disease affecting the pathogenesis of lymphoma.
Therefore, this study investigated the frequency of HHV6, its impact on clinical manifestations of lymphoma and its
possible association with risk for development of CMV infection in pediatric lymphoma patients.
Methods: Presence of HHV6 DNA and CMV DNA was investigated by PCR assay in both WBC’s and plasma
samples from 50 patients diagnosed with HL or NHL. CMV antibody titer was also determined in sera obtained
from each patient. Twenty apparently healthy siblings were used as a control group.
Results: In a study group of 50 patients diagnosed with HL or NHL, 23/50 (46%) were found to be positive for herpes
virus DNA (HHV6 or CMV) in WBC’s or plasma by PCR assay and this was significantly higher than its presence in the
pediatric control group 2/20 (10%) (p = 0.005). Ten out of these 23 (43%) were found to have active CMV infection.
Fifty six percent of patients with CMV infection were found among NHL cases with B- subtype. The presence of both
herpes viruses DNA was significantly associated with more frequent episodes of febrile neutropenia (median 3
episodes), absolute neutrophil count (< 0.8), lymphocytes (< 0.5), and low hemoglobin level (< 9.1), (p < 0.05).
Conclusion: The presence of HHV6 can be considered as a predicting indicator of cellular immunosuppression
preceding the onset of CMV infection which may result in a severe outcome among pediatric lymphoma patients.
Introduction
Human herpesvirus 6 (HHV6) was first reported in 1986,
as human B-lymphotropic virus. Name was subsequently
changed to human herpesvirus 6 as its tropism was further
characterized [1,2] and it was identified as a member of
the b family of herpes viruses [3]. Seroepidemiological sur-
veys have shown that HHV6 is highly prevalent in human
populations in different geographical areas with prevalence
varying between 70 and 100% [4]. HHV6 shares with other
members of the human Herpesviridae family an ability to
cause latent infection with reactivation during periods of
immunosuppression [5]. Also, HHV6 and CMV share a
tropism for cells of the immune system [6] and for induc-
tion of immunosuppression [7]. These similarities,
together with the ability of HHV-6 to reactivate heterolo-
gous virus [8], may explain its role in the pathogenesis of
CMV disease in an immunocompromised host, such as
post transplant patients, with respect to CMV disease and
the development of opportunistic fungal infections [8].
Pediatric clinical presentations of HHV-6 infection vary
depending upon the age and immune competence of the
child. In the immunocompromised host, the spectrum of
specific HHV6 clinical syndromes remains undefined [9]
but is associated with a worse outcome [10]. HHV6 reac-
tivation occurs in 33-48% of patients undergoing hemato-
poietic stem cell transplantation and is associated with
organ-specific diseases such as pneumonitis, hepatitis,
encephalitis, bone marrow suppression and non specific
febrile syndromes [10].
Activation of HHV6 was seen in both HL and NHL as a
result of lymphoma associated immunosuppression and
variation in its frequency was reported [11]. In National
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about the role of HHV6 infection in pediatric lymphomas
and its association with CMV activation.
For this reason the focus of this study was, i) to inves-
tigate the presence of HHV6 in white blood cells and
plasma of the children with lymphoma, ii) to study the
impact of HHV6 on the clinical features of pediatric
lymphoma disease, iii) Investigate frequency of CMV
infection and its impact upon the course of the disease.
Patients and Methods
Patients
This cross sectional study was conducted on 50 pediatric
lymphoma patients (Hodgkin’s&N o nH o d g k i n ’s) diag-
nosed and treated at the Pediatric Oncology Department,
National Cancer Institute (NCI), Cairo University between
September 2007 and October 2008. Twenty patients indi-
viduals’ were included as matched controls. The Institu-
tional Review board (IRB) of the NCI approved the
protocol. Informed written consent was obtained from
guardians of all children enrolled in the study.
The study included patients between 1 and 16 years
old of both sexes. Then, all patients were thoroughly
evaluated for clinicopathological data.
Disease extent and staging were established after a
detailed history and physical assessment. Full local and
systemic imaging surveys (X-rays, CTs, MRI) according
to disease site and clinical presentation were performed.
Gallium scan and bone marrow aspirate (±) trephine
biopsies were also performed when indicated by treat-
ment protocol. Other baseline and prognostic investiga-
tions were carried out; serum Lactate dehydrogenase
(LDH), Erythrocyte sedimentation rate (ESR), Complete
blood count (CBC), liver and renal function tests.
The Ann Arbor staging system [12] was used for
Hodgkin’s lymphoma (HL), where patients received tai-
lored courses of cychemotherapy in form of “ABVD” (±)
involved field radiation of reduced dose (25 GY) accord-
ing to their risk stratification [13].
Non Hodgkin lymphoma patients were staged accord-
ing to St Jude Children Staging System [14]. B cell lym-
phomas were risk stratified and treated according to the
SFOP (French Society of Pediatric Oncology) protocols
[15]. The BFM protocol [16] was used for T cell precur-
sor lymphoblastic lymphoma.
Patients under study have been interviewed at differ-
ent phases of therapy and medical records were
reviewed for clinical progress evaluation and data
abstraction.
Histopathology and immunohistochemistry
All 50 tumor tissue specimens were pathologically restu-
died on the basis of the examination of hematoxylin-
eosin and Giemsa-stained slides. Tumor type was
specified for each case according to the current World
Health Organization classification [17]. All cases were
further stained for basic B and T cell markers, and
immunohistochemistry for NHL sub-classification. All
cases of HL were stained for CD15 and CD30 and stain-
ing for CD20 and CD45RA was performed if NLPHL
(Nodular lymphocyte-predominant Hodgkin’sl y m -
phoma) was suspected
Specimen collection
Blood specimens were collected into tubes with EDTA
(Ethylenediaminetetraacetic acid) anticoagulant, left at
room temperature for 1 hour to sediment erythrocyte.
T h ep l a s m aw a ss e p a r a t e da n dc e n t r i f u g e da t8 0 0×g
for 10 min. Samples of plasma were stored at -20°C for
DNA extraction and detection of HCMV IgG by ELISA.
Leukocytes were isolated according to the protocol of
Vander Bij et al [18] and stored in aliquots of 100 μl
saline at -40°C until nucleic acid extraction.
Molecular detection
1 - Nucleic acid extraction
Viral DNA was extracted from both WBCs and plasma
specimens using GFX Genomic Blood DNA Purification
Kit (Amersham Biosciences, UK) according to the man-
ufacturer’s instructions. DNA extracts were placed on
ice and used immediately for PCR or stored at -40°C
until analysis. The amount of viral DNA was measured
by spectrophtometry using a Nano-Drop 2000 spectro-
photometer (Thermo Scientific/US, Canada) and 100 ng
of DNA template was used in the PCR assays.
A sample for each participant in the study was sub-
jected to one round of PCR for detection of HHV-6
DNA and nested PCR for detection of HCMV (human
cytomegalovirus) in both cells and plasma specimens.
For HHV6 positive and negative (water) controls were
run in each PCR assay. For HCMV, AD169 DNA from
CMV reference strain AD169 (American Type Culture
Collection, Rockville, Md., USA) was extracted by the
same extraction procedure and used as a positive con-
trol in the PCR assay.
2 - Amplification of HHV-6 DNA
HHV6 DNA was selectively amplified by PCR using
sequence-specific primers for a 249-bp portion of the
large-tegument protein gene of HHV-6 between nucleo-
tides 27240 and 27483 by following the method of
Osiowy et al [19]. This primer set has previously been
shown to be specific for HHV-6 and not to amplify DNA
from other members of the herpesvirus family including
(CMV), Epstein-Barr virus, varicella zoster virus and
herpes simplex viruses 1 and 2. PCRs were performed in
a final volume of 20 μl, which included 5 μlo fD N A
extract, 1 U of Taq DNA polymerase (Boehringer
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dNTPs, 10 mM Tris HCl (pH 8.3), 1.5 mM MgCl2 and
50 mM KCl. The samples were overlaid with mineral oil
to prevent evaporation.
Thermocycling conditions were as follows: (i) an initial
denaturation step of 2.5 min at 94°C; (ii) 35 cycles, with
1 cycle consisting of 30 s of denaturation at 94°C, 30 s
of annealing at 62°C, and 50 s of extension at 72°C; and
(iii) a final extension step of 5 min at 72°C. PCR was
performed in a Perkin Elmer-Cetus thermocycler.
3 - Amplification of HCMV
HCMV-DNA was detected using sequence-specific pri-
mers for a 147-bp portion of the CMV immediate early
gene between nucleotides 172750 and 172895 by the
method of Vogelberg [20]. PCR was performed using a
ready made GEN-Master Mix (BIORON, Germany). Five
μl of DNA extract was included in the reaction mixture
containing 10× Tris HCL buffer, dNTPs (0.4 mM), MgCl2
(1.5 mM), 0.02% Tween-20, 0.1 units/μl DFS-Taq DNA
polymerase (BIORON, Germany), along with 0.6 μMo f
each primer, in a final volume of 25 μl. The samples were
overlaid with mineral oil to prevent evaporation. The reac-
tion was performed in a DNA thermal cycler (Perkin
Elmer-Cetus): (i) an initial denaturation step of 9 min at
95°C; (ii) 30 cycles, with 1 min cycle consisting of 1 min of
denaturation at 95°C, 1 min of annealing at 55°C, and
1 min of extension at 72°C; and (iii) a final extension step
of 7 min at 60°C. Using 10 fold dilutions of the viral DNA,
the sensitivity of the PCR assay for CMV was determined
according to Brown [21]. The target CMV DNA could be
amplified and detected with sensitivity of 10 copies of viral
genome/ug genomic DNA [22].
4 - Detection of Amplified products by agarose gel
electrophoresis
15 μl of PCR product was subjected to electrophoresis on
a 2.5% agarose gel (Sigma) in Tris-Acetate buffer (TAE
1X) pH 8.2, stained with 0.5 ug/ml ethidium bromide and
examined under UV transillumination and photographed.
Product sizes were estimated by comparison with 100 bp
DNA ladder (Amersham, UK). Amplified fragments are
249 bp for HHV-6 (Figure 1) and 147 for HCMV [22].
Serological detection of HCMV IgG by ELISA
Analysis of serum samples for IgG antibodies to CMV
was performed using CMV biokit, S.A.08186 (Barcelona-
Spain) or bioelisa CMV IgG ELISA test according to
manufacturer’s instructions kit. The concentration of
antibodies in the sample was estimated using a calibra-
tion curve. Antibody concentration > 0.25 IU/ml
was taken to indicate immune status. A level > 2.5 was
considered a high positive and implies he had recent or
reactivated CMV infection [23].
Statistical methods
Data were statistically described in terms of median and
range or mean and standard deviation (± SD), frequen-
cies and percentages, as appropriate. Comparison of
quantitative variables was done using Mann Whitney
U test for independent samples in 2 groups and Kruskal
Wallis test in comparing more than 2 groups. For com-
paring categorical data, Chi square (Fisher’s exact) test
was performed. A p value < 0.05 was considered statisti-
cally significant. All statistical calculations were done
using SPSS version 15 (SPSS Inc., Chicago, IL, USA).
Results
The median age of the 50 pediatric lymphoma patients
was 8.5 years (range 2-18 yrs), and that of apparently
healthy siblings was 7 years (range 1-18 yrs). Preponder-
ance of males was observed among lymphoma patients
with a male to female ratio of 1.7:1, and 1.5:1 for normal
siblings. There was no significant difference between
lymphoma and normal siblings regarding age and sex
(p = 0.128 and 0.754, respectively). Clinical parameters
for lymphoma patients are summarized in Table 1. Lym-
phoma group included 17 patients with Non-Hodgkin’s
lymphoma (NHL) and 33 with Hodgkin’s disease (HL);
their subtypes are shown in Table 2. Half of the lym-
phomas cases were at an early stage of disease (stage 1
and 2) and the other half were at later stages (3, 4). Ele-
ven patients with stage 1 and 2 disease received radio-
therapy. Radiotherapy was also given to three patients
with stage 3 and 4 disease. Twenty four patients were in
induction phase of therapy, 23 were at maintenance
phase of therapy, and 3 received salvage treatment for
relapsing disease.
According to the PCR results in cells or plasma, parti-
cipants fall in one of 4 categories; those positive for H6
Figure 1 EB-stained gel electrophoresis of HHV-6-DNA PCR
product showing positive lanes (10-12) and negative lanes
(2-9). 100 bp ladder lane (1). N.B. positive signals are 249 bp., Lane
2 is negative control (water). Lane 12 is positive control
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HHV6 and CMV and those negative for both viruses.
The presence of herpes viruses (HHV6 and/or CMV) in
lymphoma patients
Herpes viruses (HHV6 and/or CMV) were present in 23
of the 50 in lymphoma patients (46%), a frequency that
was significantly higher than that in the control group
(2/20, 10%) (p = 0.005). There was no significant differ-
ence between NHL and HL groups regarding presence
of HHV6 and/or CMV (10/17, 59% vs. 13/33, 39%,
r e s p e c t i v e l y ,p=0 . 1 9 2 ) .H o w e v e r ,a ss h o w ni nt a b l e3 ,
there was a significant difference between HL and NHL
groups in the distribution of viruses (p = 0.007) with
higher frequency of the two viruses together in NHL
(47%) and higher frequency of single virus infection in
HL (15% of HHV6 and 18% of CMV, versus 6% for
each in NHL). Lymphoma patients positive for both
herpes viruses (n = 10) were 7 males and 3 females,
with a median age of 6.5 years (range, 3-13 years).
Concerning the presence of the each virus regardless
of the other, CMV infection was significantly higher in
NHL (9/17, 53%) compared to HL disease (8/33, 24%)
(p = 0.042) and HHV6 DNA (in WBCs or plasma) was
significantly higher in NHL (9/17, 53%) compared to HL
disease (7/33, 21%) (p = 0.023).
In relation to lymphoma subtypes, in HL patients, we
found that 2 (6%) patients of MC subtype were positive
for HHV6 single infection and another 2 (6%) were
positive for both HHV6/CMV. In NHL patients, we
observed that eight (47%) patients of B-lineage subtype
were positive for both herpes viruses (HHV6/CMV)
(Table 2).
There was no significant difference in CMV IgG level
between lymphoma and control groups [median 3
(0.0-7.5) vs. 2.4 (0.0-5.0), respectively, p = 0.109]. Also,
CMV IgG level was not significantly different between HL
and NHL patients (p = 0.902) (Table 3). However, CMV
viremic lymphoma patients had significantly higher CMV
IgG levels compared to those without viremia (median
value was 4.0 (0.0-7.5) vs. 2.6 (0.0-5.7), (p = 0.006).
The presence of herpes viruses (HHV6 and/or CMV) and
clinico-pathological parameters in lymphoma patients
The detailed relation between HHV6 and/or CMV
detection and clinico-pathological parameters is pre-
sented in table (IV). We compared patients negative for
both viruses to those with positive HHV6 and/or CMV
DNA. There was no significant difference between age
groups (< 9 yrs and ≥ 9 yrs) in the presence of herpes
viruses (p = 0.395). Similarly, there was no gender dif-
ference (p = 0.670) and no association between herpes
virus infection and disease stage (p = 1.000). Presence of
HHV6/CMV was significantly higher among patients
under salvage therapy compared to those under induc-
tion and maintenance chemotherapy (p = 0.034). There
was significantly higher frequency of HHV6/CMV in
patients with uncontrolled disease (stationary or pro-
gressive) (p = 0.021). Two out of 50 lymphoma patients
(4%) died, one of them was infected with HHV6 and the
other was infected with CMV (Table 4).
The presence of herpes viruses (HHV6 and/or CMV) and
some clinical parameters in lymphoma patients
Mucositis and other infections (cannula site infection,
perianal infection, fungal chest infection, herpetic skin
lesions, positive blood cultures for Candida kruis, Kleb-
siella pneumonia, mixed Candida species and Aspergillus
flavus) were significantly associated with herpes virus
infection (p < 0.001 and = 0.004, respectively). All patients
with mucositis were positive for both herpes viruses DNA
(70%), H6 alone (20%) or CMV alone (10%). On the other
hand, 58% of those with other infections were positive for
both HHV6/CMV DNA (Table 5).
Presence of both herpes viruses was associated with
more frequent episodes of febrile neutropenia (median 3
episodes vs. 0 episodes in negative herpes viruses cases)
(p = 0.006). The presence of both herpes viruses was asso-
ciated with high risk clinical parameters (long duration of
febrile neutropenia (more than 10 days) (p = 0.080),
ANC < 0.8×10
9/l (p = 0.023), lymphopenia (< 0.5 ×10
9/l)
(p = 0.008), thrombocytopenia (Plt < 96 ×10
9/l) (p =
0.137), and low Hb level (< 9.1 g/dl) (p = 0.010), more
than patients negative for herpes viruses.
Discussion
The presence of HHV6 DNA was detected in 16/50
(32%) of our lymphoma patients, 6/16 (37.5%) of these
patients were viremic. Our results were close to those
reported by Di Luca et al. who detected HHV6 DNA in
29% of their cases [24]. Sumiyoshi et al. [25] have
reported presence of HHV6 in 50-68% in patients with
different malignant lymphomas. In the current study,
the frequency of HHV6 DNA in HD cases was 21%.
This figure lies between the very higher frequencies
r e p o r t e db yV a l e n t ee ta l .( 7 3 % )[ 2 6 ]a n dt h el o wf r e -
quency (12%) reported by Torelli et al. [27]. None of
our healthy volunteers showed HHV6 infection.
Discrepancies in the results could be attributed to sev-
eral reasons: i) All these studies have investigated the
presence of HHV6 in lymphoid tissues only which indi-
cate that the virus could be activated at sites other than
peripheral blood compartment [28], ii) The wide spec-
trum of sensitivity of the techniques used in different
laboratories [26], the amount of DNA analyzed, and the
presence of variants of HHV6 which did not hybridize
well to the primers used could lead to false negative
results, iii) most of our patients had absolute neutropenia
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presence of a low number of infected cells.
In contrast with Tailor et al. [5], we observed that
there was a significant difference in frequency of HHV6
infection between NHL and HL cases (p = 0.023). Such
difference in frequency of HHV6 in both NHL and HL
might be linked to different treatment regimen given
according to type of lymphoma [5].
CMV is considered to be one of the most important
opportunistic infections occuring in lymphoma patients as
a result of impairment in cell mediated immunity [29].
CMV pneumonia (CMVp) is to be one of the most com-
mon clinical presentations of CMV disease and is asso-
ciated with considerable morbidity and mortality in
patients with hematological malignancies [30,31]; disease-
specific mortality rate reaches up to 30% in lymphoma
patients [32]. Moreover, CMV retinitis [33] encephalitis
and oesophagitis have been observed among patients with
HL and NHL diseases [34]. In contrast to Hingmire et al
(34), who reported that CMV infections are less common
in HL and NHL patients who did not undergo allogeneic
BMT, we could detect CMV infection in 34% of our lym-
phoma patients. Furthermore, it is noteworthy that the
majority of the patients in our NHL series derived from a
B-cell lineage 16/17 (94%). More than half of our NHL
patients of B cell subtype (9/16, 56%) showed CMV infec-
tion. This might be due to exposure to more selective sup-
pressive chemotherapy that leads to diminished T cell
function with the disappearance of CD8 cytotoxic popula-
tion [29]. We also observed that the antibody titer to
CMV was consistent with its reactivation from latency in
lymphoma (median value in patients with and without
CMV infection was 4, 2.6 respectively, p = 0.006).
It has been documented that the risk of developing
severe CMV disease depends on the degree of immuno-
suppression and underlying disease [35]. Previous studies
have reported that HHV6 infection is one of the major
contributions for induction of an immunosuppression
state in patients with BMT and solid organ transplanta-
tion. Multiple studies suggested association between
Table 1 Clinical and Laboratory characteristics of
pediatric lymphoma patients
Variables HL N = 33 NHL N = 17
Age (Mean ± SD) 10.5 ± 4.5 8.1 ± 4.6
Sex
Male: n = 32 18 14
Female: n = 18 15 3
M:F ratio 1:2:1 4:6:1
LFT (Mean ± SD)
ALT (IU/L) 25.2 ± 11.7 29.2 ± 12.7
AST (IU/L) 21.2 ± 11.4 21.7 ± 9.9
T. Bil (mg/dL) 1.1 ± 0.3 1.0 ± 0.4
KFT (Mean ± SD)
Creatinine (mg/dL) 0.9 ± 0.3 1.0 ± 0.3
CBC (Mean ± SD)
Hb (g/dL) 10.6 ± 2.2 7.6 ± 3.0
TLC (×109/l) 5.3 ± 3.6 2.9 ± 4.6
Plt (×109/l) 134.9 ± 79.1 171.3 ± 208.4
ANC (×109/l) 1.8 ± 1.3 1.4 ± 2.3
Mono (×109/l) 1.5 ± 1.2 0.6 ± 1.0
LDH (Mean ± SD) (IU/L) 207.4 ± 214.2 443.7 ± 667.5
ESR 1
st hr (Mean ± SD) 40.5 ± 31.1 35.4 ± 24.5
ESR 2
nd hr (Mean ± SD) 73.5 ± 63.7 65.1 ± 45.9
Phase of therapy
Induction: n = 24 15 9
Post-induction: n = 23 16 7
Salvage: n = 3 2 1
Stage of disease
I+II (n = 25) 19 6
III+IV (n = 25) 14 11
SD: Standard deviation, LFT: Liver function test, ALT: Alanin aminotransferase,
AST: Aspartate aminotransferase, T. Bil: Total bilirubin, KFT: Kidney function
test, CBC: Complete blood picture, Hb: Hemoglobin concentration, TLC: Total
leukocytic count, Plt: Platelet count, ANC: Absolute neutrophilic count, Mono:
monocyte, LDH: Lactate dehydrogenase, ESR1: Erythrocyte sedimentation rate
1
st hour, ESR2: Erythrocyte sedimentation rate 2
nd hour
Table 2 Lymphoma cases associated with HHV6 infection
and both herpes viruses
Lymphoma subtype No of cases
n(%)
HHV6
n = 6(%)
Both
n = 10(%)
NHL (n = 17)
B cell lymphoma 16(94) 1(6) 8(47)
Burkitt lymphoma 7(45) 1(6) 4(25)
Burkitt like 5(30) 0(0) 1(6)
Large B cell lymphoma 4(25) 0(0) 3(19)
T-Lymph Lymph 1(6) 0(0) 0(0)
HL (n = 33)
Mc 13(39) 2(6) 2(6)
Lp 8(24) 1(3) 0(0)
Ns 8(24) 1(3) 0(0)
Ld 4(12) 1(3) 0(0)
NHL: Non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, Mc: multicellularity,
Lp: lymphocytic predominance, Ns: nodular sclerosis, Ld: lymphocyte depletion,
HHV6: herpes virus 6 single infection, Both: positive for HHV6/CMV DNA.
Table 3 Distribution of herpes viruses as detected by PCR
HL n = 33 NHL n = 17 p value
HHV6, n(%) 5(15) 1(6) 0.007
CMV, n(%) 6(18) 1(6)
Both, n(%) 2(6) 8(47)
Negative cases, n(%) 20(61) 7(21)
CMV Ab, median (range) 2.9 (0-7.5) 3.0 (0-6.1) 0.902
NHL: Non Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, HHV6: herpes virus
6 single infection, CMV: cytomegalovirus single infection, Both: positive for
HHV6/CMV DNA, Negative: negative for herpes viruses, CMVAb:
cytomegalovirus IgG antibody titer
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tion with effects on both clinical picture and prognosis
[25,36]. These observations encouraged us to investigate
frequency of lymphoma patients positive for both herpes
viruses (HHV6/CMV) and secondly, determine if there is
a relationship between presence of both viruses and
severity of lymphoma disease. Our data showed that 20%
of lymphoma patients were positive for both herpes
viruses. Moreover, the presence of both viruses was more
common among NHL cases (8/17, 47%). Previous studies
have addressed explanations for such observations which
could be due to: (i) immunosuppression from both NHL
d i s e a s ea n di t st r e a t m e n tm a yp r e d i s p o s ep a t i e n t st o
higher risk of coinfection, (ii) An immunomodulating
effect of HHV6 since it can induce production of inter-
leukin-1b and tumor necrosis factor-alpha, suppress T
lymphocyte function due to reduced interleukin-2 synth-
esis [7], and suppress bone marrow by inducing inter-
feron-alpha production. [37,38], (iii) HHV-6 can directly
infect CD4+ T-cells and induce apoptosis, thus altering
key immune activation molecules pathways and subse-
quently disturbing the cytokine network. (iv) HHV-6 can
also infect thymic epithelial cells, hematopoietic stem
cells, and natural killer cells, which are critical for
immune maturation and protection against cancer and
viral infections.
All these factors could contribute to pathologic effects
of other viral infections like CMV as a result of HHV6
reactivation [39], and also create an environment suita-
ble for persistence of HHV6 latency [40].
T h ep r e s e n c eo fb o t hh e r p e sv i r u s e sw a sa s s o c i a t e d
with uncontrolled lymphoma disease (p = 0.021) and
salvage phase of treatment (p = 0.034) but not with
advanced stage (p = 1.000).
Griffiths et al. [41] showed that the combination of
both HHV6 and CMV infection after organ transplanta-
tion was more likely to be associated with CMV disease
than with CMV infection alone. Our observations
extended to demonstrate the immunosuppressive effect
of HHV6 and its associated clinical manifestations
among cases who had CMV infection (reactivation or
reinfection), these include: i) patients who were positive
for CMV and negative for HHV6 were older than those
with negative CMV and positive HHV6, median age were
15 y and 5.5 Y respectively. ii) 70% of patients with posi-
tive herpes viruses (HHV6, CMV) showed clinical mani-
festations of severe chest infection and were significantly
associated with more frequent episodes of febrile neutro-
penia (median 3 episodes), long duration of febrile neu-
tropenia > 10 days, absolute neutrophil count (ANC) of
< 0.8, lymphopenia (< 0.5), and low Hb concentration
( H b<9 . 1 ) .i i i )T h ep r e s e n c eo fH H V 6s i n g l ei n f e c t i o n
Table 4 Relation between demographic and disease characteristics and distribution of herpes viruses among pediatric
lymphoma patients
Factor HHV6 n(%) CMV n(%) Both n(%) Negative n(%) p value
Age
<9yn=2 5 3(12) 3(12) 7(28) 12(48) 0.395
≥9Yn=2 5 3(12) 4(16) 3(12) 15(60)
Sex
M: n = 32 3(9) 4(13) 7(22) 18(56) 0.670
F: n = 18 3(17) 3(17) 3(17) 9(50)
Stage
I+II (n = 25) 3(12) 5(20) 4(16) 13(52) 1.000
III+IV (n = 25) 4(16) 3(12) 5(20) 13(52)
Phase of therapy
Induction: n = 24 2(8) 6(25) 5(21) 11(46)
Maintenance: n = 23 3(13) 1(4) 3(13) 16(70) 0.034
Salvage: n = 3 1(33) 0(0) 2(67) 0(0)
Status of disease
CR+PR: n = 42 5(12) 6(14) 6(14) 25(60) 0.021
SD+PD: n = 8 2(25) 1(13) 4(50) 1 (13)
Outcome
Af: n = 38 4(11) 6(16) 6(16) 22(59)
Ad: n = 10 1(10) 0(0) 4(40) 5(50) *
D: n = 2 1(50) 1(50) 0(0) 0(0)
CR: Complete remission, PR: Partial remission, SD: Stationary disease, PD: Prolonged disease, Af: Alive free of disease, Ad: Alive with disease, D: Died, HHV6:
herpes virus 6 single infection, CMV: cytomegalovirus single infection, Both: positive for HHV6/CMV DNA, Negative: negative for herpes viruses
* No p value because only two patients died.
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Page 6 of 9was significantly associated with longer duration of feb-
rile neutropenia > 10 days when compared to HHV6
negative patients and did not show any significant differ-
ence when compared to those positive for both herpes
viruses. However, we could not rely completely on such
observations because all of our patients were subjected to
lymphoma treatment which could aggravate the suppres-
sive effect of HHV6, this favoring development of CMV
infection and disease and because of the lower number of
studied cases. Therefore, the role of HHV6 as a predictor
for CMV syndrome in cases with CMV infection is
needed to be carefully evaluated in a larger number of
lymphoma cases. It will be also worthy to follow the
patients before and after treatment to consider the role
of iatrogenic immunosuppression.
In the present exploratory study, a single sample was
analyzed. This could not indicate the timing, duration
and the course of infection. More frequent sampling
with quantitative analysis of peripheral blood and tissues
in follow up studies may be necessary for better deter-
mining the causal effect of this unique b-herpesvirus
relationship.
In conclusion
the presence of HHV6 could be considered as a predict-
ing indicator of cellular immunosuppression preceding
the onset of CMV infection (reactivation or reinfection)
which may result in a severe outcome among pediatric
lymphoma patients. The presence of both herpes viruses
appeared to be associated with an aggressive form of the
lymphoma disease. The severe clinical manifestations
associated with HHV6 single infection may suggest the
synergistic effect of HHV6 on CMV associated infection.
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ANC (Median = 0.8)
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Lymph
≥ 0.5 n = 25 3(12) 4(16) 1(4) 17(68) 0.089
< 0.5 n = 25 3(12) 3(12) 9(36) 10(40)
Med. Mass: Mediastinal mass, FN: Febrile neutropenia, ANC: absolute neutrophil count, Plt: Platelet count, Hb: hemoglobin concentration, Mono: monocyte,
Lymph: Lymphocyte, HHV6: herpes virus 6 single infection, CMV: cytomegalovirus single infection, Both: positive for HHV6/CMV DNA, Negative: negative for
herpes viruses
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